6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

06:43 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

06:35 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

12:17 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Feb 26 06:16 ET

6-K: Transaction in Own Shares

Feb 25 06:36 ET

6-K: Gsk Completes Acquisition of Idrx, Inc.

Feb 24 06:47 ET

6-K: Gsk Plc Commences Share Buyback Programme

Feb 24 06:37 ET

6-K: Gsk Announces Dr Gavin Screaton to Join the Board as Non-executive Director and Dr Jesse Goodman to Retire After 9 Years of Service

Feb 21 11:56 ET

6-K: 2025 Performance Share Plan Award

Feb 21 11:52 ET

6-K: Deferred Annual Bonus Plan Awards

Feb 21 11:37 ET

6-K: Transaction Notification​

Feb 21 11:22 ET

6-K: Vesting of Performance Share Plan Awards

Feb 21 11:02 ET

6-K: Vesting of Conditional Share Awards Under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares

Feb 21 07:26 ET

6-K: Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depositary Shares

Feb 21 07:22 ET

6-K: Nucala (Mepolizumab) Application for Copd Accepted for Review in China

Feb 20 06:46 ET

6-K: Penmenvy, Gsk's 5-in-1 Meningococcal Vaccine, Approved by Us Fda to Help Protect Against Menabcwy

Feb 18 06:44 ET

6-K: Transaction notification

Feb 13 14:04 ET

6-K: Transaction notification

Feb 11 14:06 ET

6-K: Gsk Delivers Strong 2024 Performance with Further Improvement to Long-Term Growth Outlook

Feb 5 12:00 ET

6-K: Total Voting Rights and Capital

Feb 3 10:19 ET